Related Experiment Video
Updated: Aug 8, 2026

A Modified Method for Heterotopic Mouse Heart Transplantion
Published on: June 23, 2014
[Heart transplantation]
Insights
Heart transplantation is standard therapy for end-stage heart failure, improving survival and quality of life. Despite challenges like limited donor access, it remains the primary biological replacement option.
Area of Science:
- Cardiology
- Transplantation Medicine
- Surgical Innovation
Background:
- Heart transplantation has evolved into standard therapy for end-stage heart failure over 30 years.
- It is recognized for both life prolongation and enhancing patient quality of life.
- The International Society for Heart and Lung Transplantation Registry reports a 79% one-year and approximately 50% 10-year survival rate.
Purpose of the Study:
- To evaluate the long-term outcomes of heart transplantation.
- To assess the survival rates in a specific heart transplant program.
- To provide context on the current status of heart transplantation versus mechanical alternatives.
Main Methods:
- Analysis of actuarial survival data from a cohort of 157 consecutive heart transplant recipients.
- Review of data from the International Society for Heart and Lung Transplantation Registry.
- Comparative analysis of heart transplantation outcomes over time.
Main Results:
- The Rigshospitalet Heart Transplant Program shows a 66% overall actuarial survival after nine years.
- A decline in heart transplant recipients was observed in the late 1990s due to limited donor availability.
- Overall one-year survival is 79%, with 10-year survival around 50% based on international registry data.
Conclusions:
- Heart transplantation remains the current standard for biological replacement in advanced heart failure.
- Technological advancements in mechanical heart replacement may offer complementary solutions in the future.
- Despite survival rates, heart transplantation significantly impacts patient longevity and quality of life.
Abstract:
In carefully selected patients with end-stage heart failure heart transplantation has developed from an experimental procedure to standard therapy during the last 30 years. It is currently accepted as a procedure for prolonging life and also for improving quality of life. According to the Registry of the International Society for Heart and Lung Transplantation the overall one-year actuarial survival is 79% and 10-year survival barely 50%. Nine years after the start of the Heart Transplant Program at Rigshospitalet the overall actuarial survival of 157 consecutive patients is 66%. Due to the limited donor access a decline of heart transplant recipients has been recorded during the late nineties. Mechanical replacement of the heart may develop from technological advances and possibly this therapy may gain a complementary status in heart failure, however the human biological replacement is currently the standard.
Related Concept Videos
Tissue Transplantation
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
Cardiomyopathy V: Interprofessional Care
Kidney Transplant I: Introduction

